Compare Alvotech's earnings swing with peers facing similar pressures by scanning our curated list of 29 resilient stocks with low risk scores that may offer steadier cash flows and cleaner balance sheets.
For an investor to stay with Alvotech, the belief is that a focused biosimilar platform can eventually turn scale into consistent cash generation. The move from net income of US$136.47 million to a loss of US$140.66 million puts execution under the microscope. The near term story now hinges on whether manufacturing upgrades and supply reliability translate into steadier revenue and less volatile earnings.
The analyst consensus Narrative on Simply Wall St leans heavily on upcoming biosimilar launches and an expanded production footprint as key near term drivers. That view meets a clear risk. The recent loss, combined with less than one year of cash runway and higher interest costs, increases pressure on Alvotech to hit its back half weighted 2026 revenue and EBITDA guidance without further disruption.
The most relevant prior context comes from Alvotech reaffirming 2026 guidance for revenue in the range of US$650 million to US$700 million and adjusted EBITDA in the range of US$180 million to US$220 million after reporting a 31% year on year decline in first half 2026 revenue to US$212 million. The latest nine month loss now sits against that ambitious framework and makes execution on product launches and supply recovery more important.
Those earlier comments on targets, together with expectations for future earnings growth, framed a thesis that operational hiccups would be temporary. The new figures challenge that assumption and make every upcoming catalyst, from scaling the upgraded Reykjavik facility to delivering limited competition biosimilars such as Simponi or Entyvio, carry more weight. For you as a shareholder, the question is how comfortable you are with that tighter margin for error around funding, leverage and delivery against guidance.
Alvotech's narrative projects forecast revenue of US$984.0 million and forecast earnings of US$202.4 million by 2029. That profile rests on analysts modeling 25.8% yearly revenue growth and an earnings move of about US$382 million from current earnings of a US$179.6 million loss.
Uncover why Alvotech's fair value indicates a 72% potential upside to its current price, which could narrow quickly.
One optimistic twist in the alternate Alvotech story is the weight placed on direct U.S. commercialization as a catalyst. The most bullish analysts had been projecting revenue of about US$1.2b and earnings of roughly US$334.9 million by 2029. That is a far brighter path than consensus, and these new losses may push you to compare both narratives more closely.
Explore 4 other Alvotech fair value estimates, including one that suggests as much as 703% upside from the current price!
Don't just follow the ticker, dig into the data and build a conviction that's truly your own.
If Alvotech has you rethinking risk, return and balance sheet strength, it can help to widen the lens and compare it with other businesses that match your preferred profile.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com